Protocol Ledger

NCT06775405 · Phase III · COMPLETED

A Study to Confirm the Effectiveness and Safety of AK0529 in Treating RSV Infections in Hospitalized Infants

Interventional Phase III clinical trial protocol NCT06775405 sponsored by Shanghai Ark Biopharmaceutical Co in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-02-29 Enrollment: 180 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06775405
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)180 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06775405
Protocol FieldVerified Registry Value
NCT IdentifierNCT06775405
Consolidated Lead SponsorShanghai Ark Biopharmaceutical Co
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment180 participants (ACTUAL)
Registered Start Date2024-02-29
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06775405
Hospital Research SiteLocationSite Profile
Beijing Children's Hospital, Capital Medical UniversityBeijing, ChinaOpen Hospital Dossier ->
Shengjing hospital of China medical universityShenyang, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI